Akero Therapeutics Inc
(NAS:AKRO)
$
25.7
0.08 (0.31%)
Market Cap: 1.78 Bil
Enterprise Value: 1.05 Bil
PE Ratio: 0
PB Ratio: 2.22
GF Score: 39/100 Akero Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022 / 04:00PM GMT
Release Date Price:
$39.85
(+3.51%)
Ed Arce
H.C. Wainwright & Co. - Analyst
Hello, and good afternoon. My name is Ed Arce, and I'm with H.C. Wainwright. And I'm pleased to have you join us for the 6th Annual H.C. Wainwright NASH Investor Conference. I'm very pleased to have our next presenting company, Akero Therapeutics, ticker AKRO. And joining me from Akero are: Andrew Cheng, the CEO; Tim Rolph, the Chief Scientific Officer; and joining us in a couple of minutes, Kitty Yale, Chief Development Officer.
So welcome, everyone.
Andrew Cheng
AKERO THERAPEUTICS, INC. - President & CEO
Thank you, Ed, for having us.
Questions & Answers
Ed Arce
H.C. Wainwright & Co. - Analyst
Absolutely, glad you're hear. So let's start with Andrew, if you could, a quick overview of Akero. And in particular, describing your potential best-in class FGF21 fusion protein EFX and its differentiated mechanism.
Andrew Cheng
AKERO THERAPEUTICS, INC. - President & CEO
Sure. I'll begin that question
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot